Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799112 | 0.80 | RORC (0.45) | ALDH1A1RORCMAPTGAA | |
| SCHEMBL6075175 | 0.78 | MAPT (0.47) | MAPTGAA | |
| SCHEMBL6074818 | 0.74 | HCRTR2 (0.45) | ALDH1A1MAPTPTPN1 | |
| Hydrochloric Acid SCHEMBL7362855 | 0.73 | HSP90AA1 (0.42) | ALDH1A1LMNASMN1; SMN2SIGMAR1PTPN1 | |
| SCHEMBL6074050 | 0.72 | ADRB2 (0.53) | RORC | |
| SCHEMBL17879690 | 0.71 | CA1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL6074241 | 0.70 | CA1 (0.44) | ALDH1A1LMNASMN1; SMN2MAPTGAA | |
| SCHEMBL6132579 | 0.68 | MEN1 (0.59) | LMNASMN1; SMN2MAPTTMEM97SIGMAR1 | |
| SCHEMBL6799938 | 0.68 | GAA (0.44) | ALDH1A1RORCLMNASMN1; SMN2MAPT | |
| SCHEMBL6801688 | 0.67 | GAA (0.62) | ALDH1A1RORCLMNAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| EP-1301482-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ALDH1A1 1091/4885RORC 1506/4885LMNA 2593/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ALDH1A1 1091/4885RORC 1506/4885LMNA 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.